LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

LQDA Sets a 2027 Revenue Marker

Chief executive officer (CEO) Roger Jeffs said Liquidia is on track for more than $1 billion in net revenues in 2027, setting a longer-term benchmark for the franchise.

Chief operating officer and chief financial officer Michael Kaseta said referrals and new patient starts have followed a linear trajectory since launch and expressed confidence that the company can maintain that pace.

For Q2, EPS of $0.74 topped the Zacks Consensus Estimate of $0.7, while revenues of $171.7 million exceeded the $165.2 million consensus. Michael Kaseta said profitability should continue growing even as investment rises.

Liquidia Sees YUTREPIA Taking Share

Roger Jeffs said YUTREPIA generated $170.4 million in Q2 net product sales, up 31% sequentially. As of July 31, Liquidia had about 5,900 unique patient prescriptions and more than 5,000 patient starts.

Jeffs added that the inhaled prostacyclin market grew from $573 million in Q1 to $607 million in Q2, while YUTREPIA approached 30% of that market on a net revenue basis.

The CEO tied the adoption to management's tolerability-dose-efficacy framework, arguing that higher tolerable dosing supports the company's confidence in continued uptake.

LQDA Broadens Commercial Reach

Chief commercial officer Scott Moomaw said the expanded sales force will increase contact with existing prescribers while pushing deeper into community settings, particularly for PH-ILD patient identification.

Moomaw also said payer access has reached broad parity, leaving product choice rather than coverage as the main commercial variable.

In Q&A, a Wells Fargo analyst asked about patient additions, while a LifeSci Capital analyst pressed on community penetration. Kaseta and Moomaw said current growth can continue, but did not commit to faster patient adds.

Liquidia Steps Up Pipeline Spending

Michael Kaseta pointed to $284.2 million of quarter-end cash and said second-half 2026 R&D expense is expected to double from the first half and rise again in 2027.

The CEO said Liquidia has 10 clinical studies underway or planned over the next 12 months across YUTREPIA and L606. He positioned L606's twice-daily dosing and tolerability profile as the next step in the franchise.

Chief medical officer Rajeev Saggar said a YUTREPIA study in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis is planned for the first half of 2027. He also said RE-WARM is designed to inform a potential Phase III path in Raynaud's phenomenon.

LQDA Addresses Litigation and Adherence

A BTIG analyst asked about the pending 327 litigation. General Counsel Russell Schundler said outcomes remain unchanged, ranging from continued commercialization if Liquidia prevails to a royalty or injunctive relief if the ruling goes against the company.

Schundler also said that management lacks visibility into the judge's timing, while Roger Jeffs reiterated confidence in Liquidia's legal arguments and probability of success.

A BofA Securities analyst questioned adherence. Jeffs said Liquidia has no current concern about discontinuation rates and expects YUTREPIA's tolerability to support adherence, while noting that more time is needed for greater detail.

Liquidia Keeps Execution at the Center

The CEO framed the quarter around sustained adoption, growing inhaled-market share and continued clinical investment, with YUTREPIA funding a broader development agenda.

Kaseta's outlook paired continued revenue growth with higher R&D and SG&A spending while maintaining a goal of growing profitability. The operating focus remains commercial scale, pipeline expansion and the 2027 revenue objective.

What Zacks Signals Say About LQDA

LQDA sports a Zacks Rank #1 (Strong Buy), the highest rank in the system, which is designed around earnings-estimate revisions and near-term outperformance potential. Its Growth Score of A is the strongest of its style readings.

You can see the complete list of today’s Zacks #1 Rank stocks here.

The Value Score of D, Momentum Score of F and VGM Score of C make the style picture mixed, since Zacks identifies an A or B Style Score as the strongest complements to Rank #1 or #2 stocks. The Zacks Rank can change as analyst estimates are revised following the just-reported results.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research